Uploaded December 2024 | Updated September 2026, 3 days ago

---

In this exciting episode, experts from across the world delve into the groundbreaking results of the FLOW study, which has significantly impacted the treatment of Chronic Kidney Disease (CKD) and cardiovascular health.

The FLOW study, the first dedicated trial to investigating a GLP-1 receptor agonist for CKD, shows incredible benefits , including a 24% reduction in kidney complications, improved heart health, and a 20% reduction in total mortality rates. Join Richard Pratley, Peter Rossing, Katherine Tuttle as they break down the latest findings and discuss how these results will shape future treatment strategies for diabetes and CKD patients. This is a game-changer for those with advanced kidney disease, with benefits extending to cardiovascular health and weight management.

To learn more on how to save kidneys, hearts and lives with the power of science, watch the video and subscribe for more EASD content.

#FLOW #diabetescare #kidneydisease #heartfailure #chronickidneydisease